araag2/HINT huggingface dataset:
Clinical trial NCT00043459 (phase 2, status: terminated)
Conditions: non-hodgkin's lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: intravenous t900607-sodium
SMILES: CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Eligibility criteria:

        Inclusion Criteria

          -  Histologically or cytologically confirmed diagnosis of non-Hodgkin's lymphoma (NHL)

          -  Subjects must have received prior chemotherapy for their NHL

          -  At least 18 years of age

          -  Bidimensionally measurable disease amenable to CT scanning. At least one lesion must
             be least 1 X 1 cm in size.

          -  Karnofsky performance status of at least 70%

          -  Estimated life expectancy of at least 12 weeks

          -  Females of childbearing potential must have a negative pregnancy test and agree to use
             an effective contraceptive

          -  Subject must be able to comply with study procedures and follow-up examinations.

          -  Signed written informed consent

          -  Lab Values (obtained ≤ 7 days prior to study enrollment):

          -  ANC at least 1.5x10e9/L,

          -  Platelet count at least 100x10e9/L,

          -  Hemoglobin at least 8.5 g/dL,

          -  Creatinine within 2 times upper limit of normal,

          -  AST and ALT within 3 times upper limit of normal,

          -  Bilirubin within 1.5 times upper limit of normal,

          -  Albumin great than 2.5 g/dL,

        Exclusion Criteria

          -  Severe, concurrent disease, infection or co-morbidity that, in the judgment of the
             investigator, would make the subject inappropriate for enrollment

          -  NYHA Class III/IV cardiac disease, left ventricular ejection fraction (LVEF) of <50%,
             or acute anginal symptoms

          -  Patients who have received any investigational agent within 4 weeks of enrollment

          -  Patients who are pregnant or breast-feeding

          -  History of prior malignancy other than NHL within the last 5 years, except for
             adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the
             cervix

          -  History of central nervous system metastases or carcinomatous meningitis

          -  Major surgery within 4 weeks of enrollment
Clinical trial NCT00694941 (phase 2, status: completed)
Conditions: amyotrophic lateral sclerosis (als)
ICD codes: G12.21
Drugs: ono-2506po
SMILES: CCCCCC[C@@H](CCC)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult male and female patients with diagnosis of ALS over the age of 18 years.

          -  Previous randomization and completion of the last visits in ONO-2506POE014 study.

          -  Patients whom the investigator has no concern and judges tolerable for the continued
             treatment with ONO-2506PO and Riluzole from a risk and benefit point of view.

        Exclusion Criteria:

          -  A clinically relevant medical history or presence of cardiovascular, gastrointestinal,
             renal, hepatic, endocrine/metabolic, neurologic, lymphatic, haematologic, immunologic,
             musculoskeletal, connective tissue, dermatologic, genito/urinary, psychiatric diseases
             or disorders that, in the opinion of the investigator may pose an unwarranted risk to
             the patient
Clinical trial NCT00343044 (phase 2, status: completed)
Conditions: ovarian cancer, fallopian tube cancer, peritoneal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C57.00, C57.01, C57.02, K65.1, K66.0, N99.4, N73.6, R88.0, Z49.32, Z49.02
Drugs: topotecan, bevacizumab
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  must have received primary taxane and platinum-based chemotherapy and no more than 1
             other chemotherapy regimen

          -  must have platinum resistant disease(defined as recurrence within 6 months of
             receiving platinum based chemotherapy, first or second line)

          -  must have measurable disease (greater than 20mm by conventional techniques or 10mm by
             spiral CT) OR elevated CA-125 (> 100 on two occasions at least one week apart

          -  performance status greater than or equal to 70%

        Exclusion Criteria:

          -  prior treatment with anti-angiogenesis agent

          -  treatment with > 2 cytotoxic regimens (including primary platinum and taxane
             chemotherapy)

          -  evidence of other malignancy within 3 years of study enrollment

          -  history of abdominal fistula, grade 4 bowel obstruction or gastrointestinal
             perforation

          -  history of intra-abdominal abscess with 6 months prior to day 0

          -  pregnant or lactating patients
Clinical trial NCT00428610 (phase 2, status: completed)
Conditions: ovarian cancer, fallopian tube cancer, primary peritoneal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C57.00, C57.01, C57.02, K65.1, K66.0, N99.4, N73.6, R88.0, Z49.32, Z49.02
Drugs: ly573636-sodium
SMILES: ClC1=CC(Cl)=C(C=C1)C(=O)NS(=O)(=O)C1=CC=C(Br)S1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal
             cancer

          -  At least 18 years old

          -  Have received at least one but no more than 2 systemic treatment regimens containing
             platinum (does not include regimens received before surgery for this cancer)

          -  Have platinum-resistant disease

        Exclusion Criteria:

          -  Have received more than 2 systemic treatment regimens for platinum-resistant disease

          -  Serious pre-existing medical conditions

          -  Actively receiving warfarin (Coumadin) for treatment of venous thrombosis or other
             prothrombotic conditions
Clinical trial NCT00410514 (phase 2, status: completed)
Conditions: lower urinary tract symptoms, bladder outlet obstruction
ICD codes: N40.2, N40.3, N40.0, N40.1
Drugs: mirabegron, placebo
SMILES: NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men 45 years of age or older

          -  Documented bladder outlet obstruction

        Exclusion Criteria:

          -  History of urinary retention

          -  Symptomatic and recurrent urinary tract infection (UTI)
Clinical trial NCT00758732 (phase 2, status: terminated)
Conditions: ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: docetaxel, carboplatin, docetaxel, liposomal doxorubicin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Reason stopped: 
    poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed ovarian cancer

          -  Stage IIIB/IV

          -  Failure to prior chemotherapy with paclitaxel /carboplatin regimen and treatment free
             interval > 6 months

          -  Presence of two-dimensional measurable disease.

          -  Life expectancy of more than 3 months.

          -  Age ≥ 18 years.

          -  Performance status (WHO) 0-2

          -  Adequate bone marrow function (Absolute neutrophil count >1000/mm^3, Platelet
             count>100000/mm^3, Hemoglobin>9gr/mm^3)

          -  Adequate liver (Bilirubin<1.5 times upper limit of normal and SGOT/SGPT<2 times upper
             limit of normal) and renal function (creatinine<2mg/dl)

          -  Informed consent

        Exclusion Criteria:

          -  Pregnant or nursing

          -  Psychiatric illness or social situation that would preclude study compliance'

          -  Other concurrent uncontrolled illness

          -  Other invasive malignancy within the past 5 years except nonmelanoma skin cancer

          -  Other concurrent investigational agents
Clinical trial NCT00023881 (phase 2, status: terminated)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: bortezomib
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    lack of efficacy
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of Philadelphia (Ph) chromosome-positive chronic myelogenous leukemia (CML)
             in chronic or accelerated phase, defined as having any of the following:

               -  Peripheral blood (PB) or bone marrow (BM) blasts at least 10% but less than 30%

               -  PB or BM blasts and promyelocytes at least 20%

               -  PB or BM basophils at least 20%

               -  Progressive splenomegaly (at least 10 cm confirmed twice at least 4 weeks apart
                  or 50% increase in splenomegaly over 4 weeks)

               -  Clonal evolution defined as the presence of additional cytogenetic abnormalities
                  other than the Ph chromosome

               -  Thrombocytopenia (platelet count less than 100,000/mm^3) unrelated to therapy

               -  Hemoglobin less than 7 g/dL unrelated to therapy or bleeding

          -  Failed prior treatment with imatinib mesylate or intolerant, unable, or unwilling to
             receive it

          -  Ineligible for higher-priority or higher-efficacy regimens or protocols

          -  No blastic phase CML

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Eastern Cooperative Oncology Group (ECOG) 0-2

        Life expectancy:

          -  At least 18 weeks

        Hematopoietic:

          -  See Disease Characteristics

        Hepatic:

          -  Bilirubin no greater than 1.5 mg/dL

        Renal:

          -  Creatinine no greater than 1.5 mg/dL OR

          -  Creatinine clearance greater than 60 mL/min

        Other:

          -  No other concurrent illness that would preclude study entry

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No more than 2 prior cytotoxic regimens in addition to imatinib mesylate and/or
             hydroxyurea

          -  At least 4 weeks since prior chemotherapy and recovered

          -  Concurrent hydroxyurea and/or anagrelide allowed during first 2 courses

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  At least 4 weeks since prior radiotherapy and recovered

        Surgery:

          -  Not specified

        Other:

          -  See Disease Characteristics

          -  See Chemotherapy

          -  At least 24 hours since prior imatinib mesylate

          -  No other concurrent investigational agents
Clinical trial NCT01395394 (phase 2, status: terminated)
Conditions: phenylketonuria
ICD codes: E70.0
Drugs: kuvan
SMILES: [H][C@@]1(CNC2=C(N1)C(=O)NC(N)=N2)[C@@H](O)[C@H](C)O
Reason stopped: 
    difficulty with recruitment and agreed with sponsor to report completed data as case reports
  
Eligibility criteria:

        Inclusion Criteria:

          -  Have read, understood, and signed this consent form (and assent form, if <18 years
             old)

          -  Are between the ages of 10-45 years

          -  Weigh at least 75 pounds (34 kg)

          -  Meet group-specific criteria

        Exclusion Criteria:

          -  Smoke

          -  Have any history of cardiovascular disease

          -  Have hepatic impairment, or demonstrate abnormal baseline liver function lab test
             results

          -  Have donated blood within 3 months prior to the study or are anemic as shown by the
             baseline lab results

          -  Are unwilling to discontinue dietary supplements (excluding medical food) two weeks
             prior to their first study visit

          -  Are currently take medications that will interfere with the interpretation of selected
             endpoints (such as lipid-lowering medication)

          -  Are currently pregnant or breastfeeding

          -  Excluding PKU, have a chronic illness, disorder, or condition (including but not
             limited to diabetes, hypertension, cancer)

          -  Have taken any investigational drug (including Kuvan for Kuvan-unresponsive
             participants & controls) within 3 months prior to the study

          -  In the opinion of the Investigator, should not be included in the study for any
             reason, including inability to follow study procedures
Clinical trial NCT00537082 (phase 2, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: fty720, placebo
SMILES: CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients aged 18-60

          -  Patients with a diagnosis of multiple sclerosis

        Exclusion Criteria:

          -  Patients with a history or presence of chronic disease of the immune system other than
             MS

          -  Patients with a history or presence of malignancy, pulmonary or heart disease, etc.

          -  Pregnant or nursing (lactating) women

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00430794 (phase 2, status: terminated)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: spironolactone
SMILES: CC1=CC(C)=C(C=C1)C(=O)OCC1=CC=C(C=C1)[C@@H](CN)C(=O)NC1=CC=C2C=NC=CC2=C1
Reason stopped: 
    difficulties with recruitment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Aged over 18 years

          -  Hypertension (essential or secondary) managed in Sheffield Hypertension Clinic or
             general practice or both.

          -  Blood pressures not adequately controlled (systolic blood pressure (SBP) >140 mmHg
             and/or diastolic blood pressure (DBP) >85 mmHg in clinic and on ambulatory blood
             pressure monitoring) despite treatment with the maximum tolerated dose of three
             antihypertensive agents.

          -  Additional antihypertensive treatment deemed appropriate by the patients' doctor.

          -  Patients' current antihypertensive treatment includes a thiazide diuretic and at least
             one of a beta-blocker, angiotensin converting enzyme inhibitor or angiotensin II
             receptor antagonist.

        Exclusion Criteria:

          -  Definite indication or contraindication for spironolactone

          -  Known Conn's syndrome (definite indication for spironolactone)

          -  Heart failure NYHA class III or IV (definite indication for spironolactone)

          -  Known hepatic failure or significant cirrhosis

          -  Known pregnancy or women planning pregnancy

          -  Women of child bearing potential not using adequate contraceptive methods

          -  Serum creatinine > 221µmol/l

          -  Serum Potassium > 5.0mmol/l

          -  Clinic blood pressure or daytime ambulatory blood pressure >240/120
Clinical trial NCT00270491 (phase 2, status: completed)
Conditions: breast cancer, neoplasm metastasis
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: paclitaxel, capecitabine
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Femal patient aged > 18 years

          -  Histologically proven breast adenocarcinoma

          -  HER2 negative receptors

          -  previously received first or second line chemotherapy for metastatic disease

          -  previously treated with anthracycline and/or docetaxel in adjuvant and/or as first or
             second line therapy

          -  presence of one or several evaluable metastatic lesion(s)

          -  presence of at least one target lesion not previously irradiated

          -  previously treated with hormonotherapy in adjuvant or in metastatic line (treatment
             will be ceased upon patient registration in the study)

          -  ECOG Performance status < 2

          -  adequate biological values

          -  patient who has clearly given her consent by signing on informed consent form prior to
             participation

        Exclusion Criteria:

          -  patient previously treated with paclitaxel or capecitabine for metastatic breast
             cancer

          -  patient with only local metastatic disease (with the exception of axillary lymph
             nodes)

          -  active symptomatic brain metastasis

          -  patient with an history of significant cardiovascular impairment (congestive heart
             failure> NYHA grade II, unstable angina or myocardial infraction within the past six
             months or serious cardiac arrhythmia)

          -  peripheric neuropathy grade ≥ 2

          -  history of another malignancy within past 5 years that could confound diagnosis or
             staging of breast cancer (with the exception of in situ cacinoma of the cervix or
             adequately treated basel cell carcinoma of the skin)

          -  patient with any medical or psychiatric condition that, in the opinion of the
             Principal Investigator, would preclude her from participating in this study

          -  patient with a known allergy to one or several of the study compounds

          -  patients who may not be regularly available due to geographical, social or family
             reasons

          -  history of renal, hepatic or metabolic pathology that could preclude with metabolism
             or elimination of the study product

          -  deficiencies of the upper intestinal tract, malabsorption syndrome

          -  patient who is pregnant, breast-feeding or using inadequate contraception
Clinical trial NCT01087476 (phase 2, status: unknown status)
Conditions: mucositis
ICD codes: J34.81, K92.81, K12.30, K12.39, K12.33, N76.81, K12.31
Drugs: doxycycline hyclate
SMILES: [H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients (> 18 years of age) with acute leukemia of recent diagnosis,scheduled
             to receive induction chemotherapy.

          -  Capacity to give written informed consent.

          -  Ability to attend the follow-up visits.

        Exclusion Criteria:

          -  Patients with allergy or intolerance to tetracyclines

          -  Patients with acute or chronic renal insufficiency (basal blood creatinine >1.9 mg/dl)

          -  Patients with the contraindication for the oral administration of drugs.

          -  Patients with active septic processes or considered resolved in less than 7 days
             before the start of chemotherapy.

          -  Patients who required tetracycline administration in the 28 days previous to
             randomization.

          -  Adult patients with acute leukemia schedule to undergo stem-cell transplantation in
             the following two weeks.

          -  Adult patients with hematological cancer with previous radiotherapy that may affect
             the salivary glands.

          -  Inability to authorize a written informed consent.

        Exclusion criteria

          -  Patients who start chemotherapy before 12 hours of the assigned treatment.

          -  Patients who have received less than 10 doses (5 days) of the assigned treatment.

          -  Requirement to receive ergot derivates.

          -  Patients who require the administration of acitretin/isotretinoin/tretinoin

          -  Patients that receive photosensitive drugs during the study period
             (hydroxyquinone/retinoids or methoxsalen)
Clinical trial NCT01357109 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: bosentan, placebo
SMILES: COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Diabetes mellitus type 2 of >2 years duration

          2. Albuminuria

        Exclusion Criteria:

          1. Age >80 years

          2. Myocardial infarction/unstable angina within three months prior to randomisation

          3. Decompensated congestive heart failure or functional class 3 and 4.

          4. Changes in dosage of any vasodilator drugs during the preceding six weeks

          5. Women of fertile age.

          6. Impaired hepatic function (2 times upper normal limit of aminotransferases ASAT and
             ALAT)

          7. Ongoing treatment with glibenclamide, cyclosporin or warfarin

          8. Any concomitant disease or condition that may interfere with the possibility for the
             patient to comply with or complete the study protocol

          9. Participant in an ongoing study

         10. Unwillingness to participate following oral and written information
Clinical trial NCT01355523 (phase 2/phase 3, status: terminated)
Conditions: breast cancer, depression
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: melatonin (n-acetyl-5-methoxytryptamine), placebo
SMILES: COC1=CC2=C(NC=C2CCNC(C)=O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    inclusion rate not as expected. not financially possible to involve other centres.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Women, age 30-75, with breast cancer who are admitted for a lumpectomy or mastectomy
             at Herlev Hospital

          -  ASA score I-III

          -  No sign of depression measured my Major Depression Inventory (MDI)

          -  Not pregnant

        Exclusion Criteria:

          -  Neoadjuvant chemotherapy

          -  Treatment with SSRI, Warfarin or other anticoagulants (except 75 mg ASA daily), MAO
             inhibitors or calcium blockers

          -  Rotor or Dubin-Johnson syndrome

          -  Epilepsy

          -  Known allergic reaction to melatonin

          -  Known and treated sleep apnea

          -  Diabetes Mellitus - insulin treated

          -  Ongoing or previous medically treated depression or bipolar disorder

          -  Known autoimmune diseases - systemic lupus erythematosus (SLE), rheumatoid arthritis
             (RA), and sclerose

          -  Incompensated liver cirrhosis

          -  Severe kidney disease

          -  Previous or current cancer

          -  Known medically treated sleep-disorder (insomnia, restless legs etc)

          -  Shift-work and night-work

          -  Daily alcohol intake of more than 5 units

          -  Pre-operative treatment with psychopharmacological drugs, opioids or anxiolytics
             (including all sleeping pills)

          -  Predicted bad compliance

          -  Pregnant or breast-feeding

          -  Pre-operative Mini Mental State Evaluation (MMSE) score less than 24